Query: Comprehensive reviews and original studies on preclinical and clinical-stage compounds targeting RPE phagocytic machinery, summarizing their mechanism specificity, in vivo efficacy in rodent or nonhuman primate models of dry age-related macular degeneration, and pharmacodynamic biomarker and tissue distribution data

The currently available evidence on compounds targeting retinal pigment epithelium (RPE) phagocytic machinery in dry age‐related macular degeneration (AMD) reveals a mix of preclinical promise and substantial gaps in clinical data. A systematic search on ClinicalTrials.gov using the query “RPE phagocytosis AND (dry AMD OR geographic atrophy)” returned no results, demonstrating that there are no registered clinical trials specifically addressing interventions that directly modulate RPE phagocytic function in dry AMD (Clinical Trials Search: RPE phagocytosis AND (dry AMD OR geographic atrophy)). This indicates that despite several mechanistic hypotheses, clinical translation remains limited, and data on mechanism specificity, in vivo efficacy, pharmacodynamic biomarkers, and tissue distribution are largely derived from preclinical studies or early-phase clinical observations outside of dedicated trials.

Several preclinical studies provide mechanistic insights relevant to RPE phagocytosis. For example, one study evaluated high-dose atorvastatin in ARPE-19 cells where the compound increased membrane fluidity and enhanced phagocytosis while reducing pro-inflammatory cytokines IL-6 and IL-8, suggesting a dual role in both ameliorating impaired phagocytosis and dampening inflammation (tian2017atorvastatinpromotesphagocytosis pages 1-2). Although this study offers promising molecular insights, it primarily relies on in vitro data, and the corresponding in vivo efficacy, pharmacodynamic biomarkers, and tissue distribution in rodent models or nonhuman primates remain inadequately characterized.

Another preclinical investigation focused on RPE phagocytic dysfunction in AMD used conditioned media derived from human umbilical tissue–derived cells (hUTC). This study demonstrated that hUTC treatment robustly rescued the defective phagocytosis observed in primary human RPE cells from AMD donors. The rescue effect was linked to receptor tyrosine kinase ligands, such as BDNF, HGF, and GDNF, and bridging molecules including MFG-E8 and TSP-1/2, which together modulated several downstream molecular pathways, including those related to apoptosis, oxidative stress, and inflammation (inana2018rpephagocyticfunction pages 1-2). However, while these findings provide mechanistic specificity and suggest potential biomarkers for RPE function, they do not extend to validated in vivo efficacy in animal models nor detail pharmacodynamic markers or tissue distribution parameters.

Comprehensive reviews addressing therapeutic strategies in dry AMD have predominantly concentrated on broader approaches such as complement inhibition, visual cycle modulation, neuroprotection, and gene therapy. Although approaches like gene therapy using AAV vectors to restore gene function in inherited models (e.g., addressing MERTK defects) have been advanced (stieger2020rpeandgene pages 270-272), these interventions target RPE dysfunction more generally rather than focusing solely on the phagocytic machinery. Similarly, interventions targeting complement components (as discussed in some reviews) indirectly impact RPE function but do not deliver segment-specific data regarding phagocytosis, in vivo efficacy in rodent or primate models, or rigorous pharmacodynamic biomarker profiles (marchesi2024differenttherapeuticapproaches pages 16-17).

Furthermore, studies discussing the role of key molecules such as RPE65 and CD36 in the regulation of phagocytosis and autophagy highlight the potential for targeted gene therapy and small-molecule approaches (si2023theroleof pages 9-10). However, these interventions remain at the mechanistic or early translational stage without comprehensive clinical validation regarding tissue distribution or robust biomarker profiles.

In summary, while there is a body of preclinical literature that defines the mechanistic specificity of certain compounds and strategies (e.g., atorvastatin and hUTC-derived factors) targeting RPE phagocytosis, and reviews suggest broader therapeutic avenues including gene therapy and complement inhibition, definitive data on in vivo efficacy in relevant animal models, along with detailed pharmacodynamic biomarker and tissue distribution analyses, remain insufficient (muller2020rpephagocytosis pages 270-272, treanorUnknownyeartheeyeas pages 115-118).

References:
1. (tian2017atorvastatinpromotesphagocytosis pages 1-2): Bo Tian, Ahmad Al-Moujahed, Peggy Bouzika, Yijun Hu, Shoji Notomi, Pavlina Tsoka, Joan W. Miller, Haijiang Lin, and Demetrios G. Vavvas. Atorvastatin promotes phagocytosis and attenuates pro-inflammatory response in human retinal pigment epithelial cells. Scientific Reports, May 2017. URL: https://doi.org/10.1038/s41598-017-02407-7, doi:10.1038/s41598-017-02407-7. This article has 34 citations and is from a poor quality or predatory journal.

2. (inana2018rpephagocyticfunction pages 1-2): George Inana, Christopher Murat, Weijun An, Xiang Yao, Ian R. Harris, and Jing Cao. Rpe phagocytic function declines in age-related macular degeneration and is rescued by human umbilical tissue derived cells. Journal of Translational Medicine, Mar 2018. URL: https://doi.org/10.1186/s12967-018-1434-6, doi:10.1186/s12967-018-1434-6. This article has 133 citations and is from a peer-reviewed journal.

3. (marchesi2024differenttherapeuticapproaches pages 16-17): Nicoletta Marchesi, Martina Capierri, Alessia Pascale, and Annalisa Barbieri. Different therapeutic approaches for dry and wet amd. International Journal of Molecular Sciences, 25:13053, Dec 2024. URL: https://doi.org/10.3390/ijms252313053, doi:10.3390/ijms252313053. This article has 8 citations and is from a peer-reviewed journal.

4. (muller2020rpephagocytosis pages 270-272): Claudia Müller and Silvia C. Finnemann. Rpe phagocytosis. Retinal Pigment Epithelium in Health and Disease, pages 47-63, Jan 2020. URL: https://doi.org/10.1007/978-3-030-28384-1\_3, doi:10.1007/978-3-030-28384-1\_3. This article has 9 citations.

5. (si2023theroleof pages 9-10): Zhibo Si, Yajuan Zheng, and Jing Zhao. The role of retinal pigment epithelial cells in age-related macular degeneration: phagocytosis and autophagy. Biomolecules, 13:901, May 2023. URL: https://doi.org/10.3390/biom13060901, doi:10.3390/biom13060901. This article has 26 citations and is from a peer-reviewed journal.

6. (stieger2020rpeandgene pages 270-272): Knut Stieger and Birgit Lorenz. Rpe and gene therapy. Retinal Pigment Epithelium in Health and Disease, pages 265-279, Jan 2020. URL: https://doi.org/10.1007/978-3-030-28384-1\_15, doi:10.1007/978-3-030-28384-1\_15. This article has 2 citations.

7. (treanorUnknownyeartheeyeas pages 115-118): R Treanor. The eye as a window to immunity. Unknown journal, Unknown year.
